. Correction to: Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 RSV Vaccine Administered 24 Months Following a Primary Dose in Adults >/=60 Years of Age. J Infect Dis 2026 Aug 14:jiag422. doi: 10.1093.
PMID: 42599736